Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6642043

Title:Double mutants of dihydrofolate reductase and methods of using same
Inventors:Bertino, Joseph R.; New York, NY, USA
Ercikan-Abali, Emine A.; New York, NY, USA
Banerjee, Debabrata; New York, NY, USA
Mineishi, Shin; New York, NY, USA
Sadelain, Michel; New York, NY, USA
Summary:This invention introduces a mutant form of human dihydrofolate reductase (DHFR), with substitutions at positions 22 and 31. Further disclosed are specific mutant forms such as Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. Applications include use of the mutant DHFR as a selectable marker, and in the genomic modification of human cells, particularly bone marrow cells or peripheral blood stem cells, and in rendering such cells resistant to the toxic chemotherapeutic effects of antifolate agents.
Abstract:New mutant forms of human dihydrofolate reductase (DHFR) which have properties superior to the previously disclosed mutants have mutations at both amino acid 22 and amino acid 31. Specific mutant forms are Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. The mutant DHFR of the invention maybe used as a selectable marker, and to modify the genome of human cells, particularly bone marrow cells or peripheral blood stem cells, to render them resistant to chemotherapy using antifolate agents.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6642043
Application Number:US1999000142530
Date Filed:20/01/1999
Date Published:04/11/2003
Assignee:Sloan-Kettering Institute for Cancer Research, New York, NY, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/23/2021